chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I was tested again as a comprehensive test and my ADMA levels had increased along with some other abnormal blood tests; I was tested again as a comprehensive test and my ADMA levels had increased along with some other abnormal blood tests; My results showed Endothelial damage that occurred within 4 months; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 26Apr2021 (Lot number: Er8736) at the age of 33 years as dose 1, single and administered in arm left, administration date 17May2021 09:00 (Lot number: Ew0177) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ASYMMETRIC DI-METHYLARGININE INCREASED (non-serious), BLOOD TEST ABNORMAL (non-serious) all with onset 2021, outcome "not recovered" and all described as "I was tested again as a comprehensive test and my ADMA levels had increased along with some other abnormal blood tests"; ENDOTHELIAL DYSFUNCTION (non-serious) with onset 2021, outcome "unknown", described as "My results showed Endothelial damage that occurred within 4 months". The events "i was tested again as a comprehensive test and my adma levels had increased along with some other abnormal blood tests", "i was tested again as a comprehensive test and my adma levels had increased along with some other abnormal blood tests" and "my results showed endothelial damage that occurred within 4 months" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of asymmetric di-methylarginine increased, blood test abnormal, endothelial dysfunction.  Additional Information: Prior to vaccination, was the patient diagnosed with COVID-19 was reported as no. Since the vaccination, has the patient been tested for COVID-19 was reported as no. Known allergies was reported as no. Other medical history was reported as No. Did the patient receive any other vaccines within 4 weeks prior to the COVID vaccine was reported as no. Reported Event: patient had Endothelial vessels tested in Mar2021 and they were fine. After receiving the vaccine, patient was tested again as a comprehensive test and patient ADMA levels had increased along with some other abnormal blood tests. patient results showed Endothelial damage that occurred within 4 months. The only thing patient did was got vaccinated. Did the adverse event result in any of the following was reported as Doctor or other healthcare professional office, clinic visit. No follow-up attempts are possible. No further information is expected.
Swelling whole body including fingers, toes also a fever and no sleep for 48hrs.  All bones felt like brused on all sides approximately 3 days.  Six hours after shot took two extra strength ibuprofen about every 4 hours. After about 16hrs took 3 antihistamine tablets and again 5 hours later.
pt recvd vax & had > 1 hr sz; septic including lp nl, ct scan nl; eeg unilateral (left sided) slowing;
area below injection side amost all the way to her elbow became red; lymph node below the arm was gettng bigger; arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (arm was sore), VACCINATION SITE ERYTHEMA (area below injection side amost all the way to her elbow became red) and VACCINATION SITE LYMPHADENOPATHY (lymph node below the arm was gettng bigger) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced VACCINATION SITE PAIN (arm was sore). On 21-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (area below injection side amost all the way to her elbow became red) and VACCINATION SITE LYMPHADENOPATHY (lymph node below the arm was gettng bigger). The patient was treated with Manual therapy (Cold packs) for Vaccination site pain; Manual therapy (Cold packs) for Vaccination site erythema and Manual therapy (Cold packs) for Vaccination site lymphadenopathy. At the time of the report, VACCINATION SITE PAIN (arm was sore), VACCINATION SITE ERYTHEMA (area below injection side amost all the way to her elbow became red) and VACCINATION SITE LYMPHADENOPATHY (lymph node below the arm was gettng bigger) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Dose 1 given on 01/20/21 lot#042L20A, Dose 2 given on 02/17/2021 lot#022M20A, , Dose 3 was given on 10/30/2021 lot#0491221A,  DOSE 4 was on June 5th, 2022  . He developed Thyroid disease in his right eye. He can't see out of that eye, he gets blurred vision. He went to the doctor when his eye started going which way 4/7/23, and medical facility misdiagnosed him. So we had to go and get a second opinion. So on May 25, 2023, we went to Dr., and she is a neuro ophthalmologist. She diagnosed him with Thyroid disease. She recommended he go back to medical facility, since we had insurance with medical facility. I had to ask to be seen by a neuro Opthamologist. He had an er visit on April 2023, unsure about the date.
i first developed a rash in B antecubital fossae.  seemed to be like atopic dermatitis and responded to topical steroids. however, i have never had atopic dermatitis. then about 1 week later on 5/29/2021, i developed a blinding headache, R sided neck pain (in the sternocleidosmastoid muscle and R ear pain). I went to the ED and had a CT scan performed. it was normal. after treatment with morphine, IVF and reglan, the headache improved. (though it did not totally resolve). i was discharged to home. the headache lingered for about 10 days . it improved after i had a 9 day course of steroids. the steroids were prescribed  because the second day after the severe headache, i developed a R sided 12 nerve palsy.  i saw my family doctor as well as a neurologist. an MRI was ordered which was normal. so, my family doctor prescribed a 9 day steroid taper. gradually, the symptoms waned. i still have a slight 12th nerve palsy but it is much better. the neurologist had no explanation for my focal neurologic findings in the face of normal labs, a normal CT and a normal MRI. he said that it was probably "postviral"
rash on the right hand like sand paper and both ankles/itchy, scratchy; may be its psoriasis; may be its eczema; rash on both ankles; This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (rash on the right hand like sand paper and both ankles/itchy, scratchy), PSORIASIS (may be its psoriasis), ECZEMA (may be its eczema) and RASH (rash on both ankles) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040BZ1A) for COVID-19 vaccination.     The patient's past medical history included No adverse effect.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On an unknown date, the patient experienced RASH PRURITIC (rash on the right hand like sand paper and both ankles/itchy, scratchy), PSORIASIS (may be its psoriasis), ECZEMA (may be its eczema) and RASH (rash on both ankles). At the time of the report, RASH PRURITIC (rash on the right hand like sand paper and both ankles/itchy, scratchy), PSORIASIS (may be its psoriasis), ECZEMA (may be its eczema) and RASH (rash on both ankles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient had scratchy on the right hand, itchy on both ankles, scratchy on both ankles after taking up the vaccine. No concomitant medications were given to the patient.   Reporter did not allow further contact
20minutes after vaccine as per patient was diaphoretic. had palpitations and dizziness. The vaccine center called a rapid response. the team transferred patient to ED. Patient stated that after he was seen by a physician ,he spent 2 hours in waiting area and then went home
throwing up; awful; headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) intramuscular, in arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization, reaction(s): "throwing up"; Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization, reaction(s): "awful", "terrible headache". The following information was reported: VOMITING (non-serious), outcome "unknown", described as "throwing up"; FEELING ABNORMAL (non-serious), outcome "unknown", described as "awful"; HEADACHE (non-serious), outcome "unknown". Therapeutic measures were taken as a result of vomiting, headache.  Additional information: Patient had a number of problems, the worst problem for the patient and this was the second time patient got a really similar cores, about 36 hours into it or after getting the vaccines, patient started throwing up, and cannot keep anything down. Patient got a terrible headache like no other headache patient. Patient tried to have treatment, but it was hard to take anything. The first day patient was able to take ibuprofen alternated with Tylenol and took some Zofran to try to not, end up throwing up the whole day again but that did not prevent it and the second day, patient could not keep anything down. The patient took things but could not keep up.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Cryptogenic stroke. While watching tv with family, I experienced numbness in the right arm and left, I had trouble speaking, and difficulty standing and walking. My spouse rushed me to the ER were I was processed and in the hospital for nearly 2 days. I had CT scans of the head and neck, EKG, and a final MRI confirming a stroke. The physical therapists assessed me and referred to me to outpatient speech therapy. Currently undergoing care by PCP, neurologist, and cardiologist to identify a diagnosis. At this time, the cardiologist has placed a 30 day heart monitor and completed an echocardiogram with bubbles. The findings were normal and I am being referred to a new cardiologist for continued follow-up with a heart loop. The neurologist also referred me to a stroke specialist for follow-up.
4/8 got vaccine. Then on 4/20 patient developed myalgias in back, legs, and jaw and headaches, tingling in hands, normal strength. Then on 4/25 developed Bells palsy treated with prednisone and valcyclovir for possible meningitis (no LP).  Full body pain particularly in LE persisted even though Bells palsy resolved. He then developed confusion and intrusive thoughts, as well as urinary retention. He was direct admitted to our hospital. Neuro exam was notable for diffuse myalgias and 1+ patellar reflexes bilaterally. Patient was treated with gabapentin for neuropathic pain control, urinary hesitancy improved, no strength deficits.  Lumbar MRI showed cauda equina enhancement consistent with ascending infectious or inflammatory process like GBM.
This spontaneous report as received from a other health professional refers to a unspecified number of patients of unknown age and gender. The patient's medical history and current conditions were not provided. On an unknown dates in approximately 2015 (reported as since 06-JUN-2015), the patients were vaccinated with a doses of oral ROTATEQ (strength, dose and frequency were not reported) lot # K012432 expiration date 20-MAY-2016 and lot # K016263, expiration date 26-JUN-2016, route defaulted to oral, that were exposed to temperatures outside of the recommended range. No adverse experience was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Moderna vaccine (NDC--8077-0273-99, lot # 048C21A) was received at store on 7/16/2021 and placed under refrigerated temperature.  3 vials were transferred to store where 20 doses were administered beyond use date.
Information has been received from a consumer concerning her nephew who on an unspecified date was vaccinated with a dose of MERUVAX vaccine(Wistar RA 27/3). Secondary suspect therapy included VARIVAX vaccine (Oka/Merck) given on an unspecified date. It was reported that the patient developed "vitaminosis", high fever and his urine had extra protein. This is one of several cases from the same source. Additional information has been requested.
Fifteen days (12/02/08) after receiving his second dose of Varivax on 11/17/08, my son developed a varicella-like lesion/blister on his forehead. On the following day (12/03/08), he developed two additional blisters. They were immediately vesicular. There was no maculo-papular stage as usually seen with the varicella-like rash of associated with vaccine adverse events. I have been treating with Caladryl lotion. He is complaining of pain and itching. Thankfully he has not had a fever.
SAME SITUATION; This spontaneous report received from a consumer concerned multiple patients. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced same situation. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of same situation was not reported. This report was non-serious. This case, from the same reporter is linked to 20220914708.
Eyes twitching, unresponsive. Fussiness, fever, decreased appetite.  6/3/09 Hospital records received DOS 5/15/09 to 5/16/09. FINAL DIAGNOSIS: Inconsolability after immunizations. Post vaccination developed fever then becoming fussy, irritable. Eyes twitch. Eating and drinking poorly. Inconsolable. Screams.  ICD-9 Codes: 78091 Fussy infant (baby) 7852 Undiagnosed cardiac murmurs. PMH:
Sunday through Wednesday I had chest pain and burn up into my throat. I am not someone to get heartburn but maybe that was it but there was a definite painful burn all the way up in my esophagus. I dealt with uti/hemorrhoids for about 2 weeks which started a couple days after the vaccine. I have had one UTI in my life, a while back and hemorrhoids have not been an issue for probably a year. These are all from the second vaccination.
Information has been received from a physician concerning a 42 year old female with a penicillin allergy and a bee sting allergy who on 02 MAY 2001 was vaccinated at her place of employment with a dose of hepatitis b vaccine recombinant (yeast) (lot # 630591/1735J). There were no concomitant medications or current illnesses. On approximately 02 MAY 2001, "not long after" vaccination, the patient experienced throat swelling and a rash. It was reported that the patient self-administered epinephrine (EPIPEN). The patient presented to an urgent care facility with an elevated pulse without angioedema or wheezing. The patient was administered IM diphenhydramine hyrochloride (Benadryl) and methylprednisolone sodium succinate (Solumedrol). It was noted that the patient recovered from her experience. The physician expressed a concern with the lot. No further information was available. Upon internal review, throat swelling was determined to be an other important medical event. The records of testing prior to release of this lot have been checked by Biological Quality Assurance and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. Additional information has been requested.
Report 2001028727-1 describes an injection site reaction in a 4 year old male who received Infanrix. Medical history and concurrent conditions were not described. Concomitant vaccines werre inactivated poliomyelitis virus vaccine, MMR. On 11/19/2001, the vaccinee received his first injection of Infanrix. On 11/21/2001, he experienced an injection site reaction characterized by a red, itchy lump 1.5 inches in diameter which was hot to touch. No medical attention was sought required. As of 11/30/2001, the outcomes of the events had resolved.
Breakthrough case of Covid-19; Breakthrough case of Covid-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). An adolescent female patient (unknown if pregnant, 12-17 Years) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "Breakthrough case of Covid-19". It was unknown if therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever, HA, chills, Body aches, N/V. Started within 12 hours of receiving vaccine.
This spontaneous report has been received from a nurse practitioner regarding a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. On an unknown date, the patient was vaccinated VARIVAX dose 1, (dose, lot # and expiry date unknown). On 23-NOV-2010, the patient received improperly stored VARIVAX dose 2, from lot # 666869/0469Z, expiry date 31-MAR-2012 (dose, vaccination site, route unknown). No adverse effects were reported. The reporter stated that inconsistencies in storage temperature were identified on extensive review and records. The reporter stated that vaccine was not thawed. The nurse practitioner reported that there was insufficient data to provide 100 percent assurance on vaccine stability. This is one of several reports received from the same reporter. Additional information has been requested.
received vaccines after a temperature excursion; This non-serious case was reported by a other health professional and described the occurrence of incorrect storage of drug in a 20-year-old patient who received DTPa (Reduced antigen) (Tdap Vaccine) (batch number 397B5) for prophylaxis.   On 08-FEB-2023, the patient received Tdap Vaccine. On an unknown date, an unknown time after receiving Tdap Vaccine, the patient experienced incorrect storage of drug (Verbatim: received vaccines after a temperature excursion). The outcome of the incorrect storage of drug was unknown.   Additional Information: GSK receipt date: 14-APR-2023 The reporter consented to follow-up. This case was for one of 119 patients, reported by same reporter. The patient received unstable vaccine after a temperature excursion, which led to incorrect storage of drug.; Sender's Comments:  US-GSK-US2023054677:same reporter US-GSK-US2023AMR055743:same reporter
Subsequent to receiving the first two doses in the serious, the pt began taking creatine monohydrate. On the day following vaccination with the third dose, the pt ate breakfast and then a few hours later experienced a headache and nausea. The pt did not seek medical attention. Additional information has been requested.
10:00 PM stiffness from injection site moves across back and shoulder area, shaking/hard to get warm, was able to fall asleep. 11:30 PM awaken to violent shaking, skin on upper body (arms/torso) feels tingly, hard to breathe (apprx. 10-15 minutes), then hot like a woman's hot flash, shaking stops and breathing returns to normal. (More pronounced than when fighting an illness with fever). Several less severe rounds of shaking then hot during the night. A mild headache not calmed with MOTRIN. Next morning 5:00 AM still a mild headache, very tired/achy. Stiffness is now back to injection site only.
Myalgia, Fever, CHILLS Narrative: CHILLS, FEVER, BODY ACHES LASTED UNTIL 1/1/2021
throat closing; panic attack; This is a spontaneous report from a contactable consumer (patient). A 29-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-119 VACCINE, Solution for injection, lot number: EP6955) via unknown route of administration on 22Mar2021 12:00 PM in right arm at dose 1 single for COVID-19 immunization at Pharmacy or Drug Store. Medical history and Concomitant medications within 2 weeks of vaccination were not reported. Patient previously took rabeprazole (ACIPHEX) and had allergy. Patient experienced sensation of throat closing and panic attack on 22Mar2021 06:45 PM. Adverse events resulted in emergency room/department or urgent care. Treatment received for the adverse events included 50MG Benadryl and shot of dexamethasone. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The outcome of events was recovering.  No follow-up attempts are possible. No further information is expected.
Noticed on day 7 after vaccine that skin over L deltoid was warm, with 2x3inch erythema without signs of infection; resolved approximately day 9 Muscle pain in Left Deltoid began on day 1, lasted approximately 72 hours
Pfizer BioNTech Bivalent COVID vaccine was administered 5 days after the 10 week refrigeration date. Vaccine expired on: 11/24/2022 and vaccine was administered on 11/29. Patient is not reporting any adverse effects,
This spontaneous report as received from a healthcare worker refers to an unspecified number of unspecified patients of unknown ages and genders. On unknown dates the patients were vaccinated with doses of GARDASIL (lot #, expiry date, route and indication unknown) that were exposed to supported temperature excursions. No adverse effect reported. This is one of several reports received from the same reporter. Additional information has been requested.
Case number PHEH2012US007255, is an initial spontaneous report received from a nurse on 23 Mar 2012: This case refers to 15-years-old female patient. She was vaccinated only Men C, Y, W-135 liquid conjugate component of MENVEO (batch number: A10062/X10067), at dose of 0.5 ml, without reconstituting with Men A component on 27 Dec 2011. No adverse event was occurred during this administration error.
12/18/2020 in PM dry cough, body aches.  Symptoms resolved on 12/19/2020
Caller is having a problem with her arms and muscles after receiving the COVID-19 vaccine last 2021; Caller is having a problem with her arms and muscles after receiving the COVID-19 vaccine last 2021; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), in 2021 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: MUSCLE DISCOMFORT (non-serious), LIMB DISCOMFORT (non-serious) all with onset 2021, outcome "unknown" and all described as "Caller is having a problem with her arms and muscles after receiving the COVID-19 vaccine last 2021".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.